GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D…more
GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D…more
Latest RNS from GSK plc
- equity_issueAdmission to Trading
- tvrTotal Voting Rights
- director_pdmrDirector/PDMR Shareholding
- clinical_trialmRNA flu vaccine candidate to advance to phase III
- clinical_trialHansoh positive 2nd Phase III results for Riz-Rez
Analyst consensus: Hold
As of 6 Oct 2026, 23 analysts rate GSK plc a Hold, with 35% buy ratings and a mean price target of 2,173p (range 1,455p–3,010p), +22% vs the current price.
Valuation vs peers
Peer-relative fair value estimate: 1,028p against a current price of 1,759p (-42%), based on EV/EBITDA.